Back HCV Disease Progression

HCV Disease Progression

EASL 2017: Direct-Acting Antivirals for Hepatitis C Not Linked to Higher Liver Cancer Risk

Hepatitis C patients treated with direct-acting antivirals (DAAs) do not appear to have a higher risk of developing liver cancer compared to those treated with interferon, and the seemingly higher rates seen in some studies are attributable to risk factors such as older age and more advanced liver disease, according to a set of studies presented at the EASL International Liver Congress this week in Amsterdam.

alt

Read more:

CROI 2017: Are HIV/HCV Coinfected People Cured with DAAs at Increased Risk for Liver Cancer?

HIV/HCV coinfected people who are successfully treated for hepatitis C using interferon-free direct-acting antiviral (DAA) therapy do not appear to have an increased likelihood of developing hepatocellular carcinoma (HCC), according to a study presented at the Conference on Retroviruses and Opportunistic Infections this month in Seattle.

alt

Read more:

AASLD 2016: Curing Hepatitis C Reduces Liver-Related Complications and Death

People with hepatitis C who achieve sustained virological response to treatment had lower liver-related morbidity and mortality rates compared to patients who were not successfully treated, according to research presented at the recent AASLD Liver Meeting.

alt

Read more:

AASLD 2016: Is DAA Treatment for Hepatitis C Reducing the Need for Liver Transplants?

Patients successfully treated for hepatitis are less likely to need liver transplants and less likely to die while on a transplant waiting list, according to studies presented at the recent AASLD Liver Meeting. A related analysis looked at the optimal timing of treatment for people awaiting transplants in order to avoid "MELD purgatory."

alt

Read more:

AASLD 2016: Liver Cirrhosis and Decompensation on the Rise Among People with Hepatitis C

Complications of advanced liver disease including cirrhosis and hepatic decompensation have risen over the past decade among people with chronic hepatitis C, according to study findings presented at the AASLD Liver Meeting in November. However, in recent years the increase has slowed, especially among those at highest risk -- black patients and people age 60 and over.

alt

Read more: